Back to Search
Start Over
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
- Source :
-
Pathology oncology research : POR [Pathol Oncol Res] 2007; Vol. 13 (1), pp. 57-62. Date of Electronic Publication: 2007 Mar 27. - Publication Year :
- 2007
-
Abstract
- To prevent acute renal failure in children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-Hodgkin's lymphoma treated according to international BFM protocols, we investigated recombinant urate oxidase (rasburicase) in the first Central European openlabeled, prospective, multicenter phase IV trial. Rasburicase was administered intravenously, at 0.2 mg/kg for 5 consecutive days to 36 patients. Blood levels of uric acid, creatinine, phosphorus, calcium, lactate dehydrogenase and complete blood count were measured daily during rasburicase treatment and on days 6, 7 and 12. Initial uric acid level decreased significantly by 4 hours (from 343 micromol/L to 58 micromol/L, p<0.001), except for one steroid-resistant patient who required hemodialysis on day 14 after having introduced combined cytostatic treatment. Comparing the data of a subgroup of 12 patients receiving rasburicase with that of a historic cohort of 14 patients treated with allopurinol indicated the superiority of rasburicase over allopurinol in prophylaxis and treatment of hyperuricemia in children with leukemia and lymphoma.
- Subjects :
- Adolescent
Allopurinol administration & dosage
Allopurinol therapeutic use
Child
Child, Preschool
Female
Humans
Hyperuricemia blood
Infant
Leukemia blood
Lymphoma, Non-Hodgkin blood
Male
Recombinant Proteins administration & dosage
Recombinant Proteins adverse effects
Recombinant Proteins therapeutic use
Urate Oxidase administration & dosage
Urate Oxidase adverse effects
Uric Acid blood
Hyperuricemia drug therapy
Hyperuricemia prevention & control
Leukemia complications
Lymphoma, Non-Hodgkin complications
Urate Oxidase therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1219-4956
- Volume :
- 13
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Pathology oncology research : POR
- Publication Type :
- Academic Journal
- Accession number :
- 17387390
- Full Text :
- https://doi.org/10.1007/BF02893442